TherapeuticsMD (TXMD) Income from Non-Controlling Interests (2024 - 2026)
TherapeuticsMD (TXMD) posted Income from Non-Controlling Interests of $517000.0 for Q1 2026, down 1.9% on a QoQ basis from $527000.0 in Q4 2025, and up 26.1% year-over-year from $410000.0 in Q1 2025.
TherapeuticsMD (TXMD) Income from Non-Controlling Interests (2024 - 2026) Analysis & Trends
TherapeuticsMD's Income from Non-Controlling Interests history runs 3 years deep, the most recent figure standing at $517000.0 for Q1 2026.
- Quarterly Income from Non-Controlling Interests rose 26.1% year-over-year to $517000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (up 42.94% YoY) and the FY2025 annual result came in at $1.8 million, up 36.61% from the prior year.
- Income from Non-Controlling Interests was $517000.0 for Q1 2026 at TherapeuticsMD, down from $527000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $534000.0 in Q3 2025 and bottomed at $275000.0 in Q3 2024.
- A 3-year average of $415125.0 and a median of $393000.0 in 2025 frame the typical range for Income from Non-Controlling Interests.
- Peak annual rise in Income from Non-Controlling Interests reached 94.18% in 2025, while the deepest fall reached 7.74% in 2025.
- TherapeuticsMD's Income from Non-Controlling Interests stood at $333000.0 in 2024, then jumped by 58.26% to $527000.0 in 2025, then retreated by 1.9% to $517000.0 in 2026.
- Business Quant data shows TXMD's Income from Non-Controlling Interests at $517000.0 in Q1 2026, $527000.0 in Q4 2025, and $534000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.64 Bn | 87.78 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.90 Bn | 32.16 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.50 Bn | 30.56 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn | 395,346.10 |
| 5 | United Therapeutics | 22.98 Bn | 20.83 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.38 Bn | 18.57 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.78 Bn | 16.46 Bn | 800.70 Mn | -12.70 Mn |
| 9 | Elanco Animal Health | 12.67 Bn | 12.24 Bn | 785.00 Mn | - |
| 10 | TherapeuticsMD | 280,418.39 | -8.14 Mn | - | 517,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 517,000.00 |
| Dec 31, 2025 | 527,000.00 |
| Sep 30, 2025 | 534,000.00 |
| Jun 30, 2025 | 376,000.00 |
| Mar 31, 2025 | 410,000.00 |
| Dec 31, 2024 | 333,000.00 |
| Sep 30, 2024 | 275,000.00 |
| Jun 30, 2024 | 349,000.00 |